Home Nav
Nextech Invest Logo

Kai Wucherpfennig

Alfred Scheidegger

Kai Wucherpfennig MD PhD is Professor and Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and Professor of Neurology at Harvard Medical School. His research focuses on the discovery of genes that control the activity of cytotoxic T cells in the tumor microenvironment drawing insights for the development of next-generation cancer immunotherapies. He has received a number of honors and awards, including his election as a Fellow in the American Society for the Advancement of Science, his election as a member of the Henry Kunkel Society at Rockefeller University, and his election as a member of the American Society for Clinical Investigation. Dr Wucherpfennig serves as an advisor to a number of immuno-oncology companies and since 2015 is an exclusive scientific board member of Nextech Invest.

 

19TH ANNUAL BIO€QUITY EUROPE

14.05. – 16.05.2018

Ghent, Belgium

  • 02.07.2018

    Kura Oncology announces closing of public offering and...

  • 29.06.2018

    Neon Therapeutics announces closing of initial public...

  • 28.06.2018

    Kura Oncology announces pricing of USD 67 million public...

Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close